AKUMS vs LYKALABS: Stock Comparison
AKUMS DRUGS AND PHARMA L is the larger company by market capitalisation. AKUMS DRUGS AND PHARMA L shows a higher ROE, a higher dividend yield and faster revenue growth, while LYKALABS shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AKUMS leads 10; LYKALABS leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AKUMS | LYKALABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AKUMS | LYKALABS |
|---|---|---|
| Live Price | ₹765.75 | ₹74.83 |
| Day Change | -1.9% | 1.19% |
| Volume | 3.39 L | 88,556 |
| 52-Week High | ₹796.55 | ₹101.99 |
| 52-Week Low | ₹409.3 | ₹44.1 |
| Distance from 52W High | -3.87% | -26.63% |
Valuation
| Metric | AKUMS | LYKALABS |
|---|---|---|
| Market Cap | ₹12,023 Cr | ₹285 Cr |
| P/E Ratio | 41.47x | 0x |
| P/B Ratio | 3.65x | 2.67x |
| EPS | ₹6.35 | ₹0.57 |
| Book Value | ₹211.64 | ₹25.12 |
| Dividend Yield | 0.13% | 0% |
Growth
| Metric | AKUMS | LYKALABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.4% | 0% |
| EPS Growth (TTM YoY) | -42.6% | 0% |
| Qtr Sales Growth | 197.4% | 0% |
| Qtr Profit Growth | 125.2% | -2.56% |
Profitability & Leverage
| Metric | AKUMS | LYKALABS |
|---|---|---|
| ROE | 4.6% | -37.11% |
| ROCE | 4.98% | -22.29% |
| Net Margin | 5.85% | -7.81% |
| Operating Margin | 11.74% | -24.74% |
| Debt to Equity | 0.01x | 0.56x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AKUMS | LYKALABS |
|---|---|---|
| Promoter Holding | 75.26% | 58.45%▲ 0.29 pp |
| FII Holding | 1.91%▲ 0.54 pp | 0.17%▼ 0.12 pp |
| DII Holding | 13.44%▼ 0.91 pp | 0.66%▼ 0.01 pp |
| Public Holding | 6.66%▲ 0.37 pp | 40.72%▼ 0.16 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AKUMS DRUGS AND PHARMA L and LYKALABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.